Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.4997/JRCPE.2020.210 http://scihub22266oqcxt.onion/10.4997/JRCPE.2020.210 32568282!?!32568282 Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32568282&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+R+Coll+Physicians+Edinb 2020 ; 50 (2): 133-137 Nephropedia Template TP {{tp|p=32568282|t=2020. Emerging pharmacotherapy for COVID-19 |pdf=|usr=}}{{32568282}} gab.com Text Emerging pharmacotherapy for COVID-19 JO: J R Coll Physicians Edinb http://www.kidney.de/pget.php?&tw=1&pmid=32568282 #FOAvip Broadly speaking, pharmacological treatments for COVID-19 can be divided into those acting on upstream pathways early on in the disease process via suppression of viral replication or by inhibiting cell entry, and those acting on downstream pathways later on via selective attenuation of the adaptive immune cytokine-mediated inflammatory response. The antiviral drug remdesivir has been shown to shorten duration of disease while interferon beta-1b may speed up viral clearance. The results with hydroxychloroquine have thus far been rather disappointing. Trials with selective cytokine blockers including anti-interleukin-1 (anti-IL-1) and anti-interleukin-6 (anti-IL-6), have shown some promise in more severe cases, with further confirmation being required from large-scale phase-3 randomised controlled trials. The likelihood is that combination therapy addressing both upstream and downstream pathways may be required to prevent progression of severe COVID-19 infection in susceptible older patients with comorbidities and we believe further studies are now warranted to specifically target such at-risk groups who are more prone to worse outcomes. Twit Text FOAVip Emerging pharmacotherapy for COVID-19 ????J R Coll Physicians Edinb http://www.kidney.de/pget.php?&tw=1&pmid=32568282 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32568282 #FOAvip English Wikipedia <ref>{{Cite pmid|32568282}}</ref> Emerging pharmacotherapy for COVID-19 #MMPMID32568282 Lipworth B; Kuo CR; Chan R J R Coll Physicians Edinb 2020[Jun]; 50 (2): 133-137 PMID32568282show ga Broadly speaking, pharmacological treatments for COVID-19 can be divided into those acting on upstream pathways early on in the disease process via suppression of viral replication or by inhibiting cell entry, and those acting on downstream pathways later on via selective attenuation of the adaptive immune cytokine-mediated inflammatory response. The antiviral drug remdesivir has been shown to shorten duration of disease while interferon beta-1b may speed up viral clearance. The results with hydroxychloroquine have thus far been rather disappointing. Trials with selective cytokine blockers including anti-interleukin-1 (anti-IL-1) and anti-interleukin-6 (anti-IL-6), have shown some promise in more severe cases, with further confirmation being required from large-scale phase-3 randomised controlled trials. The likelihood is that combination therapy addressing both upstream and downstream pathways may be required to prevent progression of severe COVID-19 infection in susceptible older patients with comorbidities and we believe further studies are now warranted to specifically target such at-risk groups who are more prone to worse outcomes. |*Betacoronavirus[MESH] |Adenosine Monophosphate/analogs & derivatives/therapeutic use[MESH] |Alanine/analogs & derivatives/therapeutic use[MESH] |Anti-Inflammatory Agents/therapeutic use[MESH] |Antiviral Agents/*therapeutic use[MESH] |COVID-19[MESH] |Coronavirus Infections/complications/*drug therapy[MESH] |Cytokines/physiology[MESH] |Enzyme Inhibitors/therapeutic use[MESH] |Humans[MESH] |Hydroxychloroquine/therapeutic use[MESH] |Pandemics[MESH] |Pneumonia, Viral/complications/*drug therapy[MESH]Emerging pharmacotherapy for COVID-19 (epmc).pdf DeepDyve Pubget Overpricing